Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 公司是专业从事动物保健品生产、销售、研发及服务的高新技术企业,是兽用金霉素行业的龙头企业。现有业务包括动物保健品业务、环保污水处理及玉米加工业务,产品种类涵盖兽用化药、兽用疫苗、动物营养品、玉米淀粉及工业污水处理服务。金河生物公司的企业愿景是成为规模领先的动保公司,为全球客户提供优质产品和服务。为实现这一目标,公司在兽用化药、兽用疫苗及宠物用药等领域积极布局新品种,开拓新赛道。 近年来,在国家兽药管理政策的支持、引导下,国内兽药企业发生明显变化,一是通过新版兽药GMP制度实施,生产管理、设施装备、质量控制能力显著提升;二是政府加强兽药行业监管工作,打击假劣兽药力度不断加大,积极营造良好兽药市场秩序;三是部分具有实力、有发展战略眼光的头部企业更加重视科技创新,通过设立研发部门,积极实施科技人才培养、引进计划,加大研发资金投入和产学研结合力度,重点开展新产品、新工艺、新技术、高质量产品的技术创新工作,有效提高了产品质量和市场占有率。 据最新统计,截止2023年2月底,通过新版兽药GMP企业1380家(即具备兽药生产资质的企业)。其中,化药和中药企业1208家,生物制品(部分企业兼产化药和中药)企业172家。与2021年相比,现阶段兽药企业共减少199家,其中化药企业减少234家,生物制品企业增加35家。另外,国际动保企业看好中国市场,一方面加大兽药新产品、新剂型、宠物药和诊断试剂注册力度,使更多产品进入国内市场,另一方面在国内建立生产基地和研发实验室,提高外资企业产品在国内市场的占有率,国内兽药企业既有发展机遇,也有竞争压力。 公司化药金霉素业务在行业中占据优势地位,随着这一轮猪周期的结束,及养殖规模化和集约化的进一步加强,金霉素未来市场空间将会逐步增加,公司在金霉素行业的龙头地位会得到进一步巩固和加强。公司兽用疫苗业务在行业中地位逐步上升,增长势头迅猛,随着未来几年新产品逐步投放市场,公司疫苗板块有望进入兽用疫苗行业的前沿。 公司积极关注宠物用药领域,目前已有部分产品上市销售,下一步将择机扩大产品种类与范围,开辟新的业务板块。 | ||||||||||||||||||||||||
Main Business | 从事动物保健品生产、销售、研发及服务的高新技术企业 | ||||||||||||||||||||||||
Legal Representative | 王东晓 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 路漫漫 | ||||||||||||||||||||||||
Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
Auditors | 信永中和会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0471-3291630 | ||||||||||||||||||||||||
Fax No | 0471-3291625 | ||||||||||||||||||||||||
Website | www.jinhe.com.cn | ||||||||||||||||||||||||
jinhe@jinhe.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 13/07/2012 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.111 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.100 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 2.879 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 3.405B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |